Bristol Myers Squibb (BMY) closed at $54.20 in the latest trading session, marking a +0.82% move from the prior day. This change outpaced the S&P 500's 0.17% loss on the day. Meanwhile, the Dow lost 0 ...

The pharmaceutical industry is promising due to AI and biotech innovations enhancing productivity, steady profits amidst ...

On Wednesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $53.76 which represents a slight increase of $0.86 or 1.63% from the prior close of $52.9. The stock opened at ...

Bristol-Myers Squibb (BMY) wins FDA nod to expand the U.S. label for its blockbuster immunotherapy Opdivo in lung cancer.

2nd October Long MKC: McCormick Extends Uptrend After Strong Q3 Earnings, Targeting Short-Term Gains 2nd October Long ES: ...

After 12 years working for big fashion brands as a Project Manager and Data Analyst,... read more.

We’re only a few months a way from the end of the year, but pharma companies still have a steady stream of clinical trial ...

IGM Biosciences Inc.'s stock tumbled 14% Tuesday, as analysts weighed in with dismay on the company's pivot away from oncology to a focus on autoimmune diseases, with at least two opting to lower ...

IGM Biosciences shifts focus to autoimmune diseases, reduces oncology research, and appoints former Bristol Myers Squibb ...

Warren Buffett is famous for being a value investor while Peter Lynch tended to be growth-oriented. Some investors are ...

Dividend investing has become increasingly popular over time, as generating regular income remains a key focus for investors.

Morgan Stanley analyst Terence Flynn has maintained their neutral stance on PRME stock, giving a Hold rating today. Terence Flynn’s ...